CRISPR–Cas-Armed Phages Could Provide a Solution...
Jul. 10, 2023
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
SNIPR Biome
Main focus: Treatment of bacterial infections
Company stage: Pre-clinical
Diseases: Bloodstream infections caused by E. coli, other infections
Genome editing tool: CRISPR-Cas
Funding stage: Private
Location: Copenhagen, Denmark
Website: https://www.sniprbiome.com/
Partners: Novo Nordisk
SNIPR Biome is a Danish, pre-clinical stage company. The company is focused on novel CRISPR-based antibacterial therapies. The company has patents on several CRISPR-Cas technologies including the Cas9, Cas3 and Cas12a enzymes. While SNIPR Biome has not revealed an official pipeline, it has disclosed the use of its DNA-based CRISPR-guided vector platform to generate next-generation antibiotic therapies.
Tags
Related News and Updates
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
